期刊
CANCER LETTERS
卷 370, 期 1, 页码 56-65出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2015.09.018
关键词
Cyproheptadine; mTOR signaling; Wnt/beta-catenin signaling; ANGPTL4; Urothelial carcinoma
类别
资金
- Ditmanson Medical Foundation Chiayi Christian Hospital, Taiwan [R100-7, R101-9]
- Ministry of Science and Technology, Taiwan [NSC99-2321-B-194-001, MOST 103-2320-B-194002, MOST 104-2314-B-194-001-MY3]
Cyproheptadine, a serotonin antagonist, has recently been reported to function as a novel therapeutic agent by inhibiting PI3K/AKT signaling in several human cancers. However, the therapeutic effect of cyproheptadine in urothelial carcinoma (UC) has never been explored. In this study, we determined the effect of cyproheptadine on the growth of five human UC cell lines and an in vivo xenograft model. The results showed that cyproheptadine exerted an inhibitory effect on the proliferation of UC cells both in vitro and in vivo. Cyproheptadine also induced cell cycle arrest in the G1 phase, subsequently followed by apoptosis and necrosis. The underlying mechanisms of cell cycle arrest were associated with the reduction of c-Myc, induction of p21 and p27, and the stabilization of Rb expression. In addition, the suppression of the GSK3 beta/TSC2/mTOR pathway and deregulation of the GSK3 beta/beta-catenin signaling were observed in cyproheptadine-treated UC cells. Furthermore, cyproheptadine-induced apoptosis was associated with ANGPTL4 expression followed by activation of caspase3 and PARP in UC cells. Our experimental results provide evidence that cyproheptadine is a suitable therapeutic agent for the treatment of UC. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据